December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Krystal Biotech, Inc. - Common Stock (NQ:KRYS)

278.92 +6.01 (+2.20%)
Streaming Delayed Price Updated: 1:12 PM EST, Jan 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Krystal Biotech, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy? ↗
This biopharma firm targets rare diseases with both approved therapies and a pipeline of clinical-stage treatments. 
Via The Motley Fool
News headline image
Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy? ↗
This biopharma firm targets rare diseases with both approved therapies and a pipeline of clinical-stage treatments. 
Via The Motley Fool
News headline image
Why a Fund Placed a $13 Million Bet on Ambarella Stock Before a 20% Post-Earnings Drop ↗
The timing looks painful, but the fundamentals tell a more complicated story about why long-term investors are still paying attention. 
Via The Motley Fool
Topics Artificial Intelligence Regulatory Compliance
News headline image
Earnings Scheduled For November 3, 2025 ↗
 
Via Benzinga
News headline image
Is IPG Photonics Stock a Buy as One Fund Builds a $9 Million Stake in the Firm? ↗
A sharp rebound in margins and profitability is testing whether patience can finally pay off for investors willing to look past years of volatility. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why One Fund Has an $8.5 Million Bet on Five9 Despite a 50% One-Year Stock Collapse ↗
The stock’s collapse tells one story, but the underlying business metrics suggest a very different long-term setup. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Up 44% Since IPO: Why a Major Fund Just Made a $45 Million Bet on This Digital Health Stock ↗
One fast-growing digital health stock just secured a notable new backer—right as its financial momentum hits a fresh gear. 
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound? ↗
One fund is quietly buying into ACADIA — just as the company posts one of its strongest quarters in years. 
Via The Motley Fool
News headline image
Soleno Turns First Profit on $66 Million in Revenue — Is This Why One Investor Just Made an $87 Million Bet? ↗
Soleno just turned profitable for the first time—right as a major fund made its move. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
$1000 Invested In Krystal Biotech 5 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Healthcare Sector Navigates Turbulent Waters: Innovation Surges Amidst Political Headwinds
New York, NY – November 10, 2025 – The S&P 500 Healthcare sector presented a mixed picture today, with the broader index showing a modest uptick while significant segments, particularly health insurers... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
News headline image
What's Driving the Market Sentiment Around Krystal Biotech Inc? ↗
 
Via Benzinga
News headline image
Krystal Biotech (KRYS) Q3 2025 Earnings Transcript ↗
Krystal Biotech (KRYS) Q3 2025 Earnings Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Krystal Biotech (KRYS) Q3 2025 Earnings Top Estimates on Strong VYJUVEK Sales ↗
Krystal Biotech's Q3 2025 earnings crushed estimates, with EPS of $2.66 and $97.8M revenue. Strong VYJUVEK sales and global expansion in Europe and Japan drive growth. 
Via Chartmill
News headline image
$1000 Invested In Krystal Biotech 5 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Expert Outlook: Krystal Biotech Through The Eyes Of 9 Analysts ↗
 
Via Benzinga
News headline image
$100 Invested In Krystal Biotech 5 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Insider Confidence Shines: Krystal Biotech and Growth Stocks with Strong Management Stakes Navigate Volatile Markets
The U.S. stock market is currently a landscape of contrasting forces, with robust bank earnings providing a bedrock of stability against the backdrop of persistent trade tensions with China and... 
Via MarketMinute
Topics Artificial Intelligence World Trade
News headline image
What's Driving the Market Sentiment Around Krystal Biotech Inc? ↗
 
Via Benzinga
News headline image
6 Stocks Goldman Sachs Says Are Poised For Potential Acquisition In Next 12 Months — Including A Huge 200% Winner ↗
Goldman Sachs has highlighted six stocks that have a high probability of being acquisition targets in the next year. 
Via Benzinga
News headline image
If You Invested $1000 In Krystal Biotech Stock 5 Years Ago, You Would Have This Much Today ↗
Krystal Biotech (NASDAQ: KRYS) has outperformed the market over the past 5 years by 16.54% on an annualized basis producing an average annual return of 31.18%. Currently, Krystal Biotech has a market... 
Via Benzinga
News headline image
Here's How Much $100 Invested In Krystal Biotech 5 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
FDA Expands Krystal Biotech Vyjuvek's Label Allowing Newborns Access To Gene Therapy For Blistering Skin ↗
The FDA approved Krystal Biotech's Vyjuvek label update, expanding treatment to newborns and offering flexible wound care based on real-world patient data. 
Via Benzinga
News headline image
If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today ↗
 
Via Benzinga
News headline image
A Glimpse Into The Expert Outlook On Krystal Biotech Through 10 Analysts ↗
 
Via Benzinga
News headline image
If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today ↗
 
Via Benzinga
News headline image
What 8 Analyst Ratings Have To Say About Krystal Biotech ↗
 
Via Benzinga
News headline image
Crude Oil Falls 1.5%; ON Semiconductor Shares Plunge After Q2 Results ↗
 
Via Benzinga
News headline image
Krystal (KRYS) Q2 Profit Jumps 143% ↗
Via The Motley Fool
News headline image
KRYSTAL BIOTECH INC (NASDAQ:KRYS) Q2 2025 Earnings Beat Estimates as VYJUVEK Drives Strong Revenue Growth ↗
Krystal Biotech (KRYS) Q2 2025 earnings beat estimates with $96M revenue and $1.29 EPS, driven by VYJUVEK success. Shares rose 4% pre-market. 
Via Chartmill
Topics Earnings
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.